Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

127 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial.
Roy D, Pratt CM, Torp-Pedersen C, Wyse DG, Toft E, Juul-Moller S, Nielsen T, Rasmussen SL, Stiell IG, Coutu B, Ip JH, Pritchett EL, Camm AJ; Atrial Arrhythmia Conversion Trial Investigators. Roy D, et al. Among authors: pritchett el. Circulation. 2008 Mar 25;117(12):1518-25. doi: 10.1161/CIRCULATIONAHA.107.723866. Epub 2008 Mar 10. Circulation. 2008. PMID: 18332267 Clinical Trial.
Randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of a single oral dose of vanoxerine for the conversion of subjects with recent onset atrial fibrillation or flutter to normal sinus rhythm: RESTORE SR.
Piccini JP, Pritchett EL, Davison BA, Cotter G, Wiener LE, Koch G, Feld G, Waldo A, van Gelder IC, Camm AJ, Kowey PR, Iwashita J, Dittrich HC. Piccini JP, et al. Among authors: pritchett el. Heart Rhythm. 2016 Sep;13(9):1777-83. doi: 10.1016/j.hrthm.2016.04.012. Epub 2016 Apr 19. Heart Rhythm. 2016. PMID: 27108936 Clinical Trial.
Prevention of symptomatic recurrences of paroxysmal atrial fibrillation in patients initially tolerating antiarrhythmic therapy. A multicenter, double-blind, crossover study of flecainide and placebo with transtelephonic monitoring. Flecainide Supraventricular Tachycardia Study Group.
Anderson JL, Gilbert EM, Alpert BL, Henthorn RW, Waldo AL, Bhandari AK, Hawkinson RW, Pritchett EL. Anderson JL, et al. Among authors: pritchett el. Circulation. 1989 Dec;80(6):1557-70. doi: 10.1161/01.cir.80.6.1557. Circulation. 1989. PMID: 2513143 Clinical Trial.
The "compensatory pause" of atrial fibrillation.
Pritchett EL, Smith WM, Klein GJ, Hammill SC, Gallagher JJ. Pritchett EL, et al. Circulation. 1980 Nov;62(5):1021-5. doi: 10.1161/01.cir.62.5.1021. Circulation. 1980. PMID: 7418152
Clinical and regulatory implications of the Cardiac Arrhythmia Suppression Trial.
Pratt CM, Brater DC, Harrell FE Jr, Kowey PR, Leier CV, Lowenthal DT, Messerli F, Packer M, Pritchett EL, Ruskin JN. Pratt CM, et al. Among authors: pritchett el. Am J Cardiol. 1990 Jan 1;65(1):103-5. doi: 10.1016/0002-9149(90)90034-x. Am J Cardiol. 1990. PMID: 1688479 Clinical Trial. No abstract available.
Symptoms at the time of arrhythmia recurrence in patients receiving azimilide for control of atrial fibrillation or flutter: results from randomized trials.
Connolly SJ, Schnell DJ, Page RL, Wilkinson WE, Marcello SR, Pritchett EL; Azimilide Supraventricular Arrhythmia Program Investigators. Connolly SJ, et al. Among authors: pritchett el. Am Heart J. 2003 Sep;146(3):489-93. doi: 10.1016/S0002-8703(03)00250-3. Am Heart J. 2003. PMID: 12947368 Clinical Trial.
127 results